Payment overview · 2025
General Payments
$277.83
14 reported records · 10 companies
Healthcare provider profile · identity verified
Nina E Bridges
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · GREENVILLE, SC · NPI 1881131829
Verified facts
What the public records show
CMS Open Payments records show Nina E Bridges received $277.83 in general payments during 2025 across 14 reported records.
Collegium Pharmaceutical, Inc. accounted for 16.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $46.68 | 16.8% | 2 | 2025 |
| Forte Bio-Pharma LLC | Unresolved — no canonical attribution shown | $36.14 | 13.0% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $32.51 | 11.7% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $30.66 | 11.0% | 2 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $28.28 | 10.2% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $27.63 | 9.9% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $25.22 | 9.1% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$19.75 | 7.1% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.56 | 6.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.40 | 5.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $277.83 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Belbuca Normalized: belbuca |
Drug | Collegium Pharmaceutical, Inc. | $46.68 | 2 | 2025 |
Source payment records
|
|||||
| NALOCET Normalized: nalocet |
Drug | Forte Bio-Pharma LLC | $36.14 | 2 | 2025 |
Source payment records
|
|||||
| PROLATE Normalized: prolate |
Drug | Forte Bio-Pharma LLC | $36.14 | 2 | 2025 |
Source payment records
|
|||||
| TANLOR Normalized: tanlor |
Drug | Forte Bio-Pharma LLC | $36.14 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $32.51 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $32.51 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $30.66 | 2 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $28.28 | 1 | 2025 |
Source payment records
|
|||||
| Advantage System Normalized: advantage system |
Device | Boston Scientific Corporation | $27.63 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $25.22 | 1 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $19.75 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $16.56 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.40 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Azithromycin | Azithromycin | 121 | 114 |
| Prednisone | Prednisone | 109 | 104 |
| Amlodipine Besylate | Amlodipine Besylate | 99 | 46 |
| Cephalexin | Cephalexin | 92 | 78 |
| Amoxicillin | Amoxicillin | 75 | 73 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 74 | 67 |
| Doxycycline Hyclate | Doxycycline Hyclate | 71 | 65 |
| Atorvastatin Calcium | Atorvastatin Calcium | 67 | 38 |
| Lisinopril | Lisinopril | 66 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 65 | 45 |
| Levothyroxine Sodium | Levothyroxine Sodium | 64 | 29 |
| Montelukast Sodium | Montelukast Sodium | 63 | 33 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 63 | 21 |
| Tramadol Hcl | Tramadol Hcl | 60 | 23 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 54 | 52 |
| Fluconazole | Fluconazole | 51 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 45 | 20 |
| Gabapentin | Gabapentin | 43 | 20 |
| Furosemide | Furosemide | 40 | 23 |
| Methylprednisolone | Methylprednisolone | 37 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 36 | 18 |
| Celecoxib | Celecoxib | 35 | 20 |
| Ondansetron Odt | Ondansetron | 35 | 25 |
| Metformin Hcl | Metformin Hcl | 33 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 32 |
| Clonazepam | Clonazepam | 32 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 32 | 26 |
| Meloxicam | Meloxicam | 31 | 17 |
| Omeprazole | Omeprazole | 31 | 18 |
| Ozempic | Semaglutide | 31 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 31 | 12 |
| Famotidine | Famotidine | 30 | 18 |
| Pregabalin | Pregabalin | 30 | suppressed |
| Nystatin | Nystatin | 29 | 14 |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Bupropion Xl | Bupropion Hcl | 25 | 12 |
| Jardiance | Empagliflozin | 25 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 25 | suppressed |
| Cefdinir | Cefdinir | 24 | 23 |
| Metformin Hcl Er | Metformin Hcl | 24 | suppressed |
| Baclofen | Baclofen | 23 | 21 |
| Losartan Potassium | Losartan Potassium | 23 | 13 |
| Carvedilol | Carvedilol | 22 | 12 |
| Eliquis | Apixaban | 22 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 21 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Simvastatin | Simvastatin | 21 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 21 | 18 |
| Lorazepam | Lorazepam | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 18 |
| Alprazolam | Alprazolam | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 18 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 18 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | 14 |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Potassium Chloride | Potassium Chloride | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $277.83 · 14 records | Collegium Pharmaceutical, Inc. | Advantage System, Belbuca, INTELLIS ADAPTIVESTIM, Leqembi, NALOCET, Ozempic, PROLATE, QULIPTA, QUTENZA, REXULTI, Rybelsus, TANLOR, UBRELVY, XIFAXAN | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error